Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Paclitaxel in HNSCC with ECOG 2
NCT07796126Phase 2Not yet recruiting
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Sep 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Barbara Ann Karmanos Cancer Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07796126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796126.